---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-177941"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:12:14.303720+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enanta Q3 net loss $18.3M ($0.85/sh); RSV topline data due Sept

## Summary
- Revenue of $18.3M from AbbVie royalties; net loss narrowed vs $22.7M Q3 2024.
- Cash & securities $204.1M; cash runway into fiscal 2028.
- RSVHR Phase 2b fully enrolled (186 patients); topline data expected September.
- IND-enabling studies ongoing for oral KIT inhibitor EPS-1421; STAT6 candidate selection in 2H 2025.
- AbbVie received FDA approval for expanded MAVYRET indication in acute HCV.

## SEC filing metadata
- accession: 0001193125-25-177941
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312525177941/0001193125-25-177941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312525177941/enta-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-177941
- JSON: https://secwatch.observer/filing/0001193125-25-177941.json
- Plain text: https://secwatch.observer/filing/0001193125-25-177941.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.